ITOS
ITeos Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
starting operations in 2012, iteos therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iteos is developing eos200271, a clinical-stage potent and selective ido1 inhibitor with exceptional brain penetration. the company is also advancing eos100850, an insurmountable and non-brain penetrant adenosine a2a receptor antagonist, into a phase 1 trial in the second half of 2018; and a human adcc-enabling anti-tigit antibody (eos884448), representing an additional, third clinical entry in 2019. based in gosselies, belgium, iteos therapeutics was founded and supported in part by investments from the ludwig institute cancer research (licr), the walloon region of belgium and the european fund for economic and regional development (feder). for more information, please visit www.iteostherapeutics.com.
Market Cap: 425 Million
Primary Exchange: NASDAQ
Website: iteostherapeutics.com
Shares Outstanding: 35.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.859164110036941
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 685 trading days
From: 2021-12-28 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|